Blog

Yan Leyfman

May 28, 2025, 17:18

Yan Leyfman: Performance Evaluation of an AI-powered System For Clinical Trial Eligibility Using mCODE Data Standards

Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:

“Honored to work with Dr. Arturo LoAIza-Bonilla and the brilliant team at Massive Bio on developing and validating an AI-powered platform that leverages GPT-4o to streamline clinical trial eligibility using mCODE 3.0 standards.

98% accuracy in tumor type

90% in extent of disease

Seamless mapping to mCODE profiles

This frontier technology can transform trial enrollment by reducing manual chart review and accelerating access to precision oncology.

This is such an important step toward automating real-world data capture and expanding clinical trial access!”

Title: Performance evaluation of an AI-powered system for clinical trial eligibility using mCODE data standards.

Authors: Yan Leyfman, Arturo Loaiza-Bonilla, Viviana Cortiana, Ertugrul Tuysuz, Selin Kurnaz, Oz Huner, Dersu Giritlioglu, Juan Pablo Noel Meza, and Cagatay Culcuoglu

You can read the Full Article on Journal of Clinical Oncology.

Yan Leyfman: Performance Evaluation of an AI-powered System For Clinical Trial Eligibility Using mCODE Data Standards

More posts featuring Yan Leyfman.

and Cagatay Culcuoglu Arturo Loaiza-Bonilla ASCO25 cancer Dersu Giritlioglu Ertugrul Tuysuz Juan Pablo Noel Meza OncoDaily Oncology Oz Huner Selin Kurnaz Viviana Cortiana Yan Leyfman

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action